
Prescient
Therapeutics
Near term opportunities.
Long term value.
Post ISCT
Science Briefing
June 2023

DISCLAIMER AND SAFE HARBOR

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this presentation. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company. Nothing in this document should be considered financial advice. Please consult your professional investment adviser who understands your risk appetite and financial objectives before considering an investment in Prescient.

The contents of this document are confidential information of Prescient. These contents are made available on a 'for your eyes only' basis to the person to whom it was sent by Prescient. The purpose of the disclosure is to facilitate commercial and confidential discussions between the disclosee and Prescient. It should not be forwarded without without the prior written consent of the Company.

Investment Highlights

World class pedigree.
We license from the best;
and work with the best

+$20M cash
Long runway for multiple catalysts

Many shots on goal for
substantial value creation

2 Targeted Therapies in clinic

- **Encouraging efficacy in cancers with unmet need**
- Orphan Drug Status

2 Cell Therapy platforms
Internal & external opportunities

Upcoming newsflow
from multiple programs

Diversified portfolio of later stage and emerging assets

Prescient Therapeutics

Targeted therapies

Ph1b drug with potential for rapid clinical development.
Encouraging activity in areas of unmet need

Cell therapy platform with demonstrated benefits ready for the clinic

Platform with potential to revolutionise cell therapy in pre-clinical development

Innovative pipeline in personalised medicine

Prescient Therapeutics

	Asset	Program	Screening	Preclinical	Phase IB	Phase II
TARGETED THERAPIES	PTX-100		TCL			
	PTX-200		AML			
CAR - T	CellPryme	CellPryme-M	Cell manufacturing enhancement			
		CellPryme-A	Adjuvant for cell therapy			
	OmniCAR	AML	CD33; CLL-1			
			Novel TCR binder (MD Anderson Cancer Center)			
		Her2+ solid tumours	Her2			
		GBM	Her2; EGFRviii			
		Platform extensions	Various			

License from the best;
Work with the best.

Prescient Therapeutics

Yale

Penn
University of Pennsylvania

University of Oxford

Moffitt Cancer Center

Peter Mac
Peter MacCallum Cancer Centre
Victoria Australia

The University of Texas MD Anderson Cancer Center
Making Cancer History

Previous collaborators include:

Memorial Sloan Kettering Cancer Center

KU Medical Center
The University of Kansas

Harvard University

National Cancer Institute

Indiana University

Einstein
Albert Einstein College of Medicine
of Yeshiva University

Department of Defense

The CAR-T process



1 Blood is collected from the patient



2 T-Cells are isolated



3 T-Cells are genetically altered to have cancer-recognising receptors (CARs)



4 Millions of CAR-T cells are grown

5 CAR-T cells are administered to the patient

Platforms to overcome CAR-T's key challenges

Prescient Therapeutics

	Challenge	OmniCAR	CellPryme
Safety / Control	No control post infusion	✓	-
Targeting	Difficulties with targeting, antigen heterogeneity	✓	-
Escape	Difficulties with mutating antigens	✓	-
Production efficiency	Cost prohibitive & slow	✓	-
Exhaustion	Cells run out of steam	✓	✓
Trafficking	Cells cannot find their way	✓	✓
Tumor penetrance	Protective layer around tumor	✓	✓✓
Tumor microenvironment	Suppresses immune cells	✓	✓✓

Safe

Effective

Sustainable

Affordable

Enduring

Strategically positioned in the rapidly moving cell therapy landscape

NOVARTIS GILEAD Bristol Myers Squibb janssen

OmniCAR CellPryme

Cells	Autologous T cells	Allogeneic cells	γδ T cells	NK cells	Others
Targets	CD19	BCMA	Others		
Indications	B cell lymphomas	Multiple myeloma	Other hematological malignancies	Solid tumours	Non-oncology diseases
Transduction method	Lentivirus	Electroporation	Transposons	Others	

Current

In development

International Society
ISCT
Cell & Gene Therapy®

Prescient Therapeutics

Presenters

Dr Rebecca Lim
Senior VP – Scientific Affairs



Dr Kevin Sek
Postdoctoral Researcher

Prescient Therapeutics

OmniCAR

Universal, Next Generation CAR-T

OmniCAR: flexible, modular CAR platform

Prescient Therapeutics



Penn
University of Pennsylvania

Associate Professor
Daniel J. Powell, Jr

Professor
Andrew Tsourkas

University of Oxford

OmniCAR: Control Features

Modular and covalent architecture of OmniCAR enables true **post-infusion control** of CAR functionality

Dose Titration



Control activity to **safe and efficacious** levels

On/off switch



Turn therapy on/off/on without killing or re-administering cells
= safety & persistence

Target Re-direction



Re-direct cells from one cancer target to another in vivo

Multi-Antigen Targeting



Target **multiple cancer antigens simultaneously** for thorough cancer killing

Concept to be tested in human under well controlled clinical trial(s) in compliance with regulatory requirements.

OmniCAR, a universal CAR T cell therapy utilizing covalent SpyCatcher/SpyTag binding to target multiple antigens in different tumors

Kevin Sek[1,2], Jun-Ming Tong[1,2], Christina Scheffler[1,2], Jasmine Li[1,2], Steven Yatomi-Clarke[3], Rebecca Lim[3], Philip K, Darcy[1,2]

1. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 2. Sir Peter MacCallum Department of Oncology, University of Melbourne, Victorian

Comprehensive Cancer Centre; 3. Prescient Therapeutics Limited, Melbourne, Australia

‘Arming’ OmniCAR™ T cells against multiple tumor antigens through rapid and spontaneous covalent SpyTag/SpyCatcher bond formation



Summary

- OmniCAR can be armed with at least 3 different binders at a time
- Arming is efficient
- Important in targeting cancers with multiple antigens (e.g. solid tumours)

Precise control of anti-tumor function and killing by OmniCAR T cells against multiple different solid and liquid tumors



Summary

- OmniCAR tumour killing can be precisely controlled by varying the binder dose
- This is the sort of “dose response” seen in with conventional medicines, but not possible with regular CAR-T therapies.
- Controlled activity is good for patients and clinicians

Tumour killing: Glioblastoma



- Titratable, armed killing by OmniCAR T cells in GBM
- **Precise control**: increased binder = increased tumour killing

Tumour killing: AML



- Unarmed OmniCAR **remained inactive**
- OmniCAR armed with CD33 binder exhibits **dramatic tumour killing**

Live snapshots of OmniCAR killing tumours

Red = live tumour cells
Green = dead tumour cells



Summary

In GBM:

- Effective killing using either binder (Her2 & EGFRviii)

In AML:

- Rapid killing by OmniCAR armed with CD33 binder

Specific activity and targeted re-direction

Prescient Therapeutics

Armed against EGFRviii



Armed against HER2



Mixed antigen coculture



Summary

- Mix of two different GBM cells (mimicking the heterogeneity of the disease in humans)
- Arming OmniCAR with either binder only killed the tumour population being targeted
- Demonstrated ability to switch from one target to another by switching binders

Altering binder doses can optimise CAR-T cell engraftment and formation of memory cells

Arming OmniCAR post transfer



Amount of OmniCAR cells in blood







Summary

- *In vivo* dosing translates directly to OmniCAR arming
- Lower doses of binder translated to better persistence
- Higher doses of binder can result in a reduction of memory T cells (CD45RO+)

Resting OmniCAR T cells prior to dosing of binders drives potent anti-tumor efficacy





Summary

- OmniCAR cells rested for 3 weeks
- No activity without binder; tumour grew quite large
- OmniCAR can be armed at will
- Arming drives **immediate & potent tumour killing**

Summary

- OmniCAR leverages the flexibility and versatility of antibody binders and spontaneous covalent bond formation to **target multiple antigens** and **tumour types**.
- The ability to target multiple antigens **simultaneously** or **re-direct** to a second antigen addresses **tumour escape and heterogeneity**.
- The **precision** afforded through dose-response ‘arming’ allows for **titratable** CAR-T activity to **address toxicities** post-transfer.
- Finally, introducing a ‘**rest**’ phase prior to arming OmniCAR cells leads to:
  - Reduced exhaustion
  - Better engraftment
  - Better memory phenotype
  - More potent anti-tumour efficacies

Prescient Therapeutics

CellPryme

CELL THERAPY ENHANCEMENTS



1 Blood is collected from the patient



2 T-Cells are isolated



3 T-Cells are genetically altered to have cancer-recognising receptors (CARs)

CellPryme-M



4 Millions of CAR-T cells are grown

CellPryme-A

5 CAR-T cells are administered to the patient

Improving CAR-T cell efficacy in a preclinical model of breast cancer through modified manufacturing methods and adjuvant therapy

Jasmine Li[1,2], Jun-Ming Tong[1,2], Kevin Sek[1,2], Christina Scheffler[1,2], Steven Yatomi-Clarke[3], Said Sebti[3], Rebecca Lim, Philip K. Darcy[1,2]

1. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 2. Sir Peter MacCallum Department of Oncology, University of Melbourne, Victorian Comprehensive Cancer Centre; 3. Prescient Therapeutics Limited, Melbourne, Australia

More memory cells required for clinical efficacy

- Clinical efficacy of CAR-T therapy remains dependent on the T cell phenotype
- It is possible to control this during the manufacturing step



CellPryme™ enriches for central memory CD4+ and CD8+ T cells within 24 hours of pretreatment









Summary

- When added to activated T cells, CellPryme enriches for central memory T cells
- Both CD4+ and CD8+ compartments benefit

Cellular pathways altered by CellPryme-M™ within 24 hours



CellPryme–M protects CAR-T cells against exhaustion following repeated antigen challenge



Summary

- CAR-T cells were repeatedly challenged with tumour cells
- CellPryme-M protected them from exhaustion (central memory cells retained)
- CellPryme-M reduced PD-1 in T cells (good for anti-tumour activity)

CellPryme™ pretreatment improves tumour killing and confers survival benefit *in vivo*

Prescient Therapeutics



Summary

- CellPryme-M improves CAR-T tumour killing
- CellPryme-M improves survival
- Mouse models had intact immune systems

CellPryme™ pretreated CAR-T cells retain central memory phenotype *in vivo* and upregulate chemokine receptors















Summary

Even after the CellPryme-M CAR-T cells are administered to mice, the favourable cell profiles persist *in vivo:*

- More Tcm cells; less Tem cells
- Less PD-1
- More chemokines (helps T cells locate the tumours)

CellPryme-A addresses the hostile Tumour Microenvironment (TME)

- TME is the **complex ecosystem** surrounding solid tumours and the origins of blood cancers (e.g. bone marrow, spleen, lymph nodes)
- Protects and nurtures the cancer
- Acts as a **protective "force field"** that bluntens the effectiveness of cancer therapies



CellPryme™ reduces Tregs and significantly boosts *in vivo* CAR-T expansion







Reduces problematic Treg cells
(that extinguish immune responses against cancer)

Significantly more CAR-T cells **penetrate the tumour**

Dramatically increases CAR-T **expansion**

CellPryme-A attenuates the Tumour Microevironment (TME) without compromising the CAR-T cells







Modifies the TME but DOES NOT impact CAR-T cell stem/memory…

…nor CAR-T cell **exhaustion**…

…but reduces the amount of CAR-T cells in the tumour that are **terminally exhausted**.

CellPryme-A significantly improves survival and works synergistically with CellPryme-M pretreated CAR-T



Experimental end point

Tumour size > 150 mm^2 or ≤ 28 days unless other humane endpoints are reached



CellPryme-A significantly boosts CAR-T tumour killing and host survival





- Conventional CAR-T had no benefit unless used with CellPryme-A
- Greatest benefit was using CellPryme-M & A together (highly significant benefit)

Summary

- CellPryme™ is a small molecule compound that can **improve CAR-T efficacy**
- **Improves tumour killing and improves survival**

CellPryme-M
can be briefly added to standard manufacturing processes

- Enriches for **favorable Tcm**
- **Less exhaustion;** improved **trafficking**

CellPryme-A
is used as an adjuvant alongside cellular immunotherapy

- Addresses the **immunosuppressive TME**
- Significantly boosts **CAR-T expansion** within the host & **penetration into tumours**

- CellPryme-M & -A can be used **separately**, but have **significant synergies** when used together
- Can be used to enhance 3rd party programs

Summary

CellPryme Complements OmniCAR

Prescient Therapeutics

OmniCAR

- Multi-targeting
- Redirection
- Control & safety
- Any target; any cell



Next generation
Cell therapies

CellPryme-M

Process that produces a better <u>cell type</u>

- Persistence
- Trafficking



Current generation cell therapies

CellPryme-A

Adjuvant therapy

- Reduces Tregs
- Primes TME for cell therapy
- Boosts CAR-T cell expansion *in vivo*

Top-down analysis is sensible for investors



Oncology*
- 2021: US$ 280bn
- 2029: US$ 536bn (8.2% CAGR)

Cell Therapies (CAR-T)
- >US$37bn by 2028^

Prescient Therapeutics
- Next gen platforms
- Enhancing 3rd party programs
- Scalable
- Controllable
- Any target; any cell
- Top pedigree

*Precedence Research 2021
^GlobalData

Diversified portfolio of later stage and emerging assets

Prescient Therapeutics

Targeted therapies

- PTX-100
  - Exciting opportunity in TCL
  - Could leap deep into clinical development
  - US Orphan Drug designation
- PTX-200 in AML

OmniCAR

- Next gen universal CAR platform
- Any cell
- Any target
- Controllable
- 3rd party opportunities

CellPryme

- Enhancing current & next-gen cell therapies
- Manufacturing enhancements
- Adjuvant therapy
- 3rd party opportunities
- Clinic ready

Investment Summary

World class pedigree.
We license from the best;
and work with the best

+$20M cash
Long runway for multiple catalysts

Many shots on goal for
substantial value creation

2 Targeted Therapies in clinic

- **Encouraging efficacy in cancers with unmet need**
- Orphan Drug Status

2 Cell Therapy platforms
Internal & external opportunities

Upcoming newsflow
from multiple programs


Prescient
Therapeutics
Thank you!
ASX code: PTX
www.ptxtherapeutics.com